Improvements were also seen in complete response rates, duration of response, and time to next treatment
The injectable borofalan (10B), developed by CNNC Headway—a subsidiary of China Isotope & Radiation Corporation (CIRC) under the China National Nuclear Corporation (CNNC)—has officially entered Phase I clinical trials
India in the Changing Landscape of Life-Sciences Research & Development
The trial aims to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the combination therapy
UNLOXCYT is an evolution in checkpoint inhibition and is now available for the treatment of adults in the U.S. with mCSCC or laCSCC who are not candidates for curative surgery or curative radiation
BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
CARsgen is working to transform outcomes for patients with solid tumors by advancing the potential of CAR T technologies
The findings, from the SPACE study, paved the way for FDA approval of AJOVY for pediatric patients aged 6-17 years weighing 45 kilograms
The study showed a statistically significant reduction in Valsalva left ventricular outflow tract (LVOT) gradient at Week 28 compared with placebo
Subscribe To Our Newsletter & Stay Updated
